Effect of SGLT2 inhibitor (Lusefi) on diabetic nephropathy Stratified analysis based on different original renal function category
Latest Information Update: 22 Nov 2021
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms CHAT-Lu
- 19 Nov 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Jan 2018 New trial record